ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1744

Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom

Urwah Ahmed1, Katharine Kalap2 and Hilary Johnson3, 1Gloucestershire Hospitals NHS Foundation Trust, Aylesbury, United Kingdom, 2Princeton University, Princeton, 3Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Access to care, Health Services Research, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations)

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Earlier diagnosis and treatment of Rheumatoid Arthritis (RA) improve patient outcomes including pain, disability and overall mortality (NICE, 2024). The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) has set a target for those with suspected early inflammatory arthritis to be assessed in a Rheumatology clinic within three weeks (NICE, 2024). The National Early Inflammatory Arthritis Audit (NEIAA) gathers data assessing this target. In 2023, this target was met for 38% nationally, and for only 10% within our trust, Gloucestershire Hospitals NHS Foundation Trust (GHNFT) (NEIAA, 2023). Low initial diagnostic accuracy (50% in our sample) once seen in the Rheumatology clinic further delays reaching an accurate final diagnosis.

Novel methods are required to supplement  the scheduling and diagnostic systems currently used in clinical practice. Locally, GHNFT requests serological data at the point of referral, but this is not used to inform decisions about prioritising patients for review. Nationally, the NEIAA has gathered service-level data including serological tests and final diagnoses for almost a decade. In combination, there is scope to use these data to develop an artificial intelligence (AI) algorithm that both prioritises patients at highest risk of RA for early Rheumatology review, and for making a more accurate initial diagnosis. We collaborated with colleagues at Princeton University to develop such an algorithm, using neural nets (NN). 

Methods: Our NN was trained on cleaned, formatted, anonymised serological data of a sample of 1000 patients from the GHNFT, gathered over the past 18 months. We used a unique technique of clustering training losses for label error detection to remove mislabelled data from our dataset and increase accuracy. The data was labelled with a 4-tier diagnosis system: 1 = confirmed EIA, 2 = possible EIA, 3 =low possibility of EIA, and 4 =not EIA. All patient identifiers were removed before being sent outside of the NHS. 

Our NN had architecture 5-32-4, batch size 10 over 1000 epochs. We trained on 1-4 tiered labels and binarised labels (0-1 scale: 0 = not EIA, previously 2, 3 & 4, 1=definitely EIA, previously 1).

Results: A 50.9% accuracy was achieved for the 4-tier labels and 87.6% for binary labels, using 5-way cross validation. Scheduling, highlighted as key usage for  the algorithm, showed a predicted 41.6% improvement in a KPI of waiting times for high-risk patients. 

Conclusion: We have developed an AI algorithm that promises to aid in both scheduling more timely appointments for high-risk patients, and increasing diagnostic accuracy once seen in the Rheumatology service. As large volumes of data are already routinely collected by NEIAA, there is further scope to train the neural nets to align clinical practices with the national quality standards set by NICE. Implementation would begin with a small-scale regional pilot programme to test economic and clinical viability, ensuring that all stakeholders are consulted throughout; as such a transformative change will undoubtedly require taking into account a myriad of ethical and political considerations. 

Supporting image 1

Methodology for Machine Learning Framework


Disclosures: U. Ahmed: None; K. Kalap: None; H. Johnson: None.

To cite this abstract in AMA style:

Ahmed U, Kalap K, Johnson H. Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/artificial-intelligence-a-novel-tool-in-the-belt-for-improving-rheumatoid-arthritis-outcomes-in-the-national-health-service-united-kingdom/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/artificial-intelligence-a-novel-tool-in-the-belt-for-improving-rheumatoid-arthritis-outcomes-in-the-national-health-service-united-kingdom/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology